Results 201 to 210 of about 846,289 (308)

Spatial variation in the mutation rate within the plant shoot apical meristem. [PDF]

Proc Natl Acad Sci U S A
Amundson KR, Marimuthu MPA, Nguyen O, Sarika K, DeMarco IJ, Phan A, Henry IM, Comai L.   +7 more
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Low mutation rate but high male-bias in the germline of a short-lived opossum. [PDF]

Genetics
Peña-García Y, Wang RJ, Raveendran M, Harris RA, Samollow PB, Rogers J, Hahn MW.   +6 more
europepmc   +1 more source

Evidence of Site-Specific and Male-Biased Germline Mutation Rate in a Wild Songbird. [PDF]

Genome Biol Evol, 2023
Zhang H, Lundberg M, Tarka M, Hasselquist D, Hansson B.   +4 more
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Reply to: Re-evaluating evidence for adaptive mutation rate variation. [PDF]

Nature, 2023
Monroe JG, Murray KD, Xian W, Srikant T, Carbonell-Bejerano P, Becker C, Lensink M, Exposito-Alonso M, Klein M, Hildebrandt J, Neumann M, Kliebenstein D, Weng ML, Imbert E, Ågren J, Rutter MT, Fenster CB, Weigel D.   +17 more
europepmc   +1 more source

The Rate of Mutations of Human Genes [PDF]

Hereditas, 2006
openaire   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Population size interacts with reproductive longevity to shape the germline mutation rate. [PDF]

Proc Natl Acad Sci U S A
Zhu L, Beichman A, Harris K.
europepmc   +1 more source

A mutation rate model at the basepair resolution identifies the mutagenic effect of polymerase III transcription. [PDF]

Nat Genet, 2023
Seplyarskiy V, Koch EM, Lee DJ, Lichtman JS, Luan HH, Sunyaev SR.   +5 more
europepmc   +1 more source